Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor-Reference-Cited by-同舟云学术

Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor

Published:2019-05-10 Issue:11 Volume:62 Page:5547-5561
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Knegtel Ronald¹^ORCID,Charrier Jean-Damien¹,Durrant Steven¹,Davis Chris¹,O’Donnell Michael¹,Storck Pierre¹,MacCormick Somhairle¹,Kay David¹,Pinder Joanne¹,Virani Anisa¹,Twin Heather¹,Griffiths Matthew¹,Reaper Philip¹,Littlewood Peter¹,Young Steve¹,Golec Julian¹,Pollard John¹

Affiliation:

1. Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00426

Reference45 articles.

1. Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

2. How do real tumors become resistant to cisplatin?

3. ATR signalling: more than meeting at the fork